237 related articles for article (PubMed ID: 36865545)
1. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Meazza R; Ruggeri L; Guolo F; Minetto P; Canevali P; Loiacono F; Ciardelli S; Bo A; Luchetti S; Serio A; Zannoni L; Retière C; Colomar-Carando N; Parisi S; Curti A; Lemoli RM; Pende D
Front Immunol; 2023; 14():1111419. PubMed ID: 36865545
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
4. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
5. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
6. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT.
Sivori S; Carlomagno S; Falco M; Romeo E; Moretta L; Moretta A
Blood; 2011 Apr; 117(16):4284-92. PubMed ID: 21355085
[TBL] [Abstract][Full Text] [Related]
8. The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.
Parisi S; Lecciso M; Ocadlikova D; Salvestrini V; Ciciarello M; Forte D; Corradi G; Cavo M; Curti A
Front Immunol; 2017; 8():1330. PubMed ID: 29097997
[TBL] [Abstract][Full Text] [Related]
9. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
10. Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy.
Ruggeri L; Parisi S; Urbani E; Curti A
Front Immunol; 2015; 6():479. PubMed ID: 26528283
[TBL] [Abstract][Full Text] [Related]
11. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
[TBL] [Abstract][Full Text] [Related]
12. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
[TBL] [Abstract][Full Text] [Related]
13. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
14. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
15. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.
Ruggeri L; Mancusi A; Capanni M; Urbani E; Carotti A; Aloisi T; Stern M; Pende D; Perruccio K; Burchielli E; Topini F; Bianchi E; Aversa F; Martelli MF; Velardi A
Blood; 2007 Jul; 110(1):433-40. PubMed ID: 17371948
[TBL] [Abstract][Full Text] [Related]
16. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells.
Locatelli F; Pende D; Mingari MC; Bertaina A; Falco M; Moretta A; Moretta L
Front Immunol; 2013; 4():15. PubMed ID: 23378843
[TBL] [Abstract][Full Text] [Related]
17. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Parisi S; Ruggeri L; Dan E; Rizzi S; Sinigaglia B; Ocadlikova D; Bontadini A; Giudice V; Urbani E; Ciardelli S; Sartor C; Cristiano G; Nanni J; Zannoni L; Chirumbolo G; Arpinati M; Lewis RE; Bonifazi F; Marconi G; Martinelli G; Papayannidis C; Paolini S; Velardi A; Cavo M; Lemoli RM; Curti A
Front Immunol; 2021; 12():804988. PubMed ID: 35173709
[TBL] [Abstract][Full Text] [Related]
19. Natural killer-cell KIR repertoire reconstitution after haploidentical SCT.
Stern M; de Angelis C; Urbani E; Mancusi A; Aversa F; Velardi A; Ruggeri L
Bone Marrow Transplant; 2010 Nov; 45(11):1607-10. PubMed ID: 20173785
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
